Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

Medical Literature

Is Biochemical Recurrence a Surrogate for Overall Survival in Localized Prostate Cancer?

Medical Literature

Intraprostatic Insertion of Fiducial Marker May Be Safer Than Previously Thought

Medical Literature

Can MRI Improve Detection of Clinically Significant Prostate Cancer?

News

Precision Radiation Technique for Prostate Cancer May Reduce Short-Term Toxicity

News

ASCOBT 2023: Can Exercise and Psychotherapy Improve Sexual Health in Patients With Prostate Cancer?

News

Diagnostic and Treatment Disparities Among Hispanic Men With Metastatic Prostate Cancer

Medical Literature

Can Combining Transrectal Ultrasound and Pelvic Floor Muscle Exercise Improve Postoperative Urinary Incontinence?

Sandy Srinivas, MD, on Treatment Alternatives for Metastatic Castration-Resistant Prostate Cancer During Radioligand Therapy Shortage

Tanya Dorff, MD, on Androgen Deprivation, External-Beam Radiation Therapy, and Oligometastatic Hormone-Sensitive Prostate Cancer

View More

Advertisement

JNCCN Spotlights

Darolutamide

Lutetium Lu-177 Vipivotide Tetraxetan

(UPDATE) Apalutamide in Prostate Cancer

(UPDATE) Degarelix (Injectable GnRH Antagonist)

(2nd UPDATE) Enzalutamide

(1st UPDATE) Enzalutamide

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

Degarelix (Injectable GnRH Antagonist)

View More

More

News

Predicting Recurrence of Prostate Cancer With PSMA PET Imaging

ASCOBT 2023: Clinical Implications of Dosimetric Feasibility Study of Radiotherapy for Prostate Cancer

ASCOBT 2023: Radiomic Model May Improve the Ability to Predict Prostate Cancer Recurrence

Prostate Cancer Prognosis in Asian Versus White Men

ASCOBT 2023: Can Exercise Improve Quality of Life in Patients on Androgen-Deprivation Therapy?

Primary Survival Analysis of ENZAMET: Role of Enzalutamide in Testosterone Suppression in Prostate Cancer

Using Artificial Intelligence to Map Cancer in the Prostate

Beyond Brachytherapy: Does Adding EBRT Benefit Those With Intermediate-Risk Prostate Cancer?

View More

Advertisement

Published

Medical Literature

Prostate Cancer Risk Prediction Tools and How to Accommodate for Missing Risk Factor Data

Radiotherapy for Prostate Cancer and Risk of Second Primary Cancer

Do Homologous Recombination Deficiency Scores Have Prognostic Value in Aggressive Prostate Cancer?

Study to Compare Radical Prostatectomy Techniques: Focus on Intraoperative Frozen Section

View More

Ongoing

CE Activities

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting

Talk to Someone: Explore Talking to Patients About Prostate Cancer Treatment

Prostate Cancer: Optimizing Timely Diagnoses and Treatment Decision-Making

View More

Available

Clinical Trials

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

View More

Resources

For Your Patients

Prostate Health Education Network

Urology Care Foundation

Cancer Support Community

Prostate Cancer Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.